0001209191-20-054822.txt : 20201014
0001209191-20-054822.hdr.sgml : 20201014
20201014175631
ACCESSION NUMBER: 0001209191-20-054822
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201012
FILED AS OF DATE: 20201014
DATE AS OF CHANGE: 20201014
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kauffman Michael
CENTRAL INDEX KEY: 0001364719
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 201239846
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 85 WELLS AVENUE, SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-12
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001364719
Kauffman Michael
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON
MA
02459
1
1
0
0
Chief Executive Officer
Common Stock
2020-10-12
4
M
0
1424
0.033
A
757913
I
By Spouse
Common Stock
2020-10-12
4
M
0
6076
0.033
A
763989
I
By Spouse
Common Stock
2020-10-12
4
S
0
7500
14.891
D
756489
I
By Spouse
Common Stock
555122
D
Stock Option (right to buy)
0.033
2020-10-12
4
M
0
1424
0.00
D
2020-10-31
Common Stock
1424
0
I
By Spouse
Stock Option (right to buy)
0.033
2020-10-12
4
M
0
6076
0.00
D
2020-10-31
Common Stock
6076
0
I
By Spouse
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.71 to $15.16, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on November 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.
/s/Christopher B. Primiano, Attorney-in-Fact for Michael Kauffman
2020-10-14